{"id":"capecitabine-cyclophosphamide","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Hand-foot syndrome"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-20%","effect":"Fatigue"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Capecitabine's mechanism of action is similar to that of 5-fluorouracil, a thymidylate synthase inhibitor. Cyclophosphamide's mechanism of action involves the formation of DNA cross-links, which prevent DNA replication and transcription. This leads to cell death, particularly in rapidly dividing cancer cells.","oneSentence":"Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Cyclophosphamide is an alkylating agent that attaches an alkyl group to the DNA of cancer cells, thereby interfering with their replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:48:39.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Advanced colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT03585465","phase":"PHASE1, PHASE2","title":"Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-03-26","conditions":"Childhood Solid Tumor","enrollment":63},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT06829199","phase":"PHASE2","title":"A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-26","conditions":"Early Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT06085742","phase":"PHASE2","title":"BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2023-11-22","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT06409390","phase":"PHASE2","title":"Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-08-14","conditions":"Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT02810743","phase":"PHASE3","title":"Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-01-25","conditions":"Breast Cancer","enrollment":174},{"nctId":"NCT04443348","phase":"PHASE2","title":"Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laura M. Spring, MD","startDate":"2020-12-16","conditions":"Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)","enrollment":120},{"nctId":"NCT06245889","phase":"PHASE2","title":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-05-01","conditions":"Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT04335669","phase":"PHASE3","title":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lund University Hospital","startDate":"2019-12-20","conditions":"Breast Cancer, Triple Negative Breast Neoplasms","enrollment":325},{"nctId":"NCT05876065","phase":"NA","title":"Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer","status":"RECRUITING","sponsor":"Wenjin Yin","startDate":"2023-06-01","conditions":"Advanced Breast Cancer","enrollment":86},{"nctId":"NCT01354522","phase":"PHASE3","title":"TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2011-05","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT03169790","phase":"PHASE1, PHASE2","title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Non Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT03169764","phase":"PHASE1, PHASE2","title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03175666","phase":"PHASE1, PHASE2","title":"QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT06839560","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined with VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients with Advanced HER2-Negative Breast Cancer with Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-01","conditions":"Brain Metastasis from Advanced HER2-negative Breast Cancer","enrollment":102},{"nctId":"NCT03169777","phase":"PHASE1, PHASE2","title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT03563144","phase":"PHASE2","title":"QUILT-3.088: NANT Pancreatic Cancer Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Metastatic Pancreatic Cancer","enrollment":""},{"nctId":"NCT03167177","phase":"PHASE1, PHASE2","title":"QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Melanoma","enrollment":""},{"nctId":"NCT03169738","phase":"PHASE1, PHASE2","title":"QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-02","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03197584","phase":"PHASE1, PHASE2","title":"QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT03197571","phase":"PHASE1, PHASE2","title":"QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Urothelial Carcinoma","enrollment":""},{"nctId":"NCT03167164","phase":"PHASE1, PHASE2","title":"QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Merkel Cell Carcinoma","enrollment":""},{"nctId":"NCT06800391","phase":"PHASE2","title":"Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2024-11-22","conditions":"Pseudomyxoma Peritonei","enrollment":31},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06771609","phase":"PHASE2","title":"Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer.","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-09-10","conditions":"Advanced Triple-negative Breast Cancer","enrollment":150},{"nctId":"NCT04534218","phase":"PHASE2","title":"Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2020-10-16","conditions":"Colo-rectal Cancer, Metastatic Cancer","enrollment":49},{"nctId":"NCT05462613","phase":"PHASE2, PHASE3","title":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2023-05-09","conditions":"Metastatic Colorectal Cancer","enrollment":446},{"nctId":"NCT03329248","phase":"PHASE1, PHASE2","title":"QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-11-06","conditions":"Pancreatic Cancer","enrollment":6},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT06102824","phase":"PHASE2","title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-10-01","conditions":"HER2-negative Breast Cancer, Advanced Breast Cancer","enrollment":252},{"nctId":"NCT03586869","phase":"PHASE1, PHASE2","title":"QUILT-3.080: NANT Pancreatic Cancer Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-07-17","conditions":"Pancreatic Cancer","enrollment":3},{"nctId":"NCT03387085","phase":"PHASE1, PHASE2","title":"QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-03-19","conditions":"Triple Negative Breast Cancer","enrollment":9},{"nctId":"NCT03387111","phase":"PHASE1, PHASE2","title":"QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-01-09","conditions":"Squamous Cell Carcinoma","enrollment":4},{"nctId":"NCT03136406","phase":"PHASE1, PHASE2","title":"QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-08-11","conditions":"Pancreatic Cancer","enrollment":3},{"nctId":"NCT03387098","phase":"PHASE1, PHASE2","title":"QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-12-28","conditions":"Pancreatic Cancer","enrollment":4},{"nctId":"NCT06373744","phase":"","title":"Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2023-01-01","conditions":"Breast Cancer","enrollment":597},{"nctId":"NCT02954055","phase":"PHASE2","title":"MEtronomic TrEatment Option in Advanced bReast cAncer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2017-09-13","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT06229067","phase":"PHASE2","title":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-19","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":182},{"nctId":"NCT04350021","phase":"","title":"Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2019-03-01","conditions":"Breast Cancer Metastatic, Chemotherapy Effect","enrollment":40},{"nctId":"NCT01873833","phase":"PHASE2","title":"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2013-07-29","conditions":"HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer","enrollment":10},{"nctId":"NCT00665457","phase":"PHASE2","title":"Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2004-04-15","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT04304352","phase":"PHASE2","title":"Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"2011-07-29","conditions":"Advanced Breast Cancer","enrollment":162},{"nctId":"NCT05774886","phase":"PHASE1","title":"Implantable Microdevice for TNBC - Pilot Study","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-05","conditions":"Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III","enrollment":""},{"nctId":"NCT00129935","phase":"PHASE3","title":"EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2004-02","conditions":"Breast Cancer","enrollment":1384},{"nctId":"NCT03518242","phase":"PHASE1","title":"Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-06-06","conditions":"Breast Cancer Female, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":100},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT04389073","phase":"PHASE2","title":"Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-04-01","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT00365417","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""},{"nctId":"NCT00544765","phase":"PHASE3","title":"Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2002-09","conditions":"Breast Cancer","enrollment":2014},{"nctId":"NCT04498793","phase":"PHASE2","title":"Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-09","conditions":"HER2-negative Breast Cancer","enrollment":55},{"nctId":"NCT00727441","phase":"PHASE2","title":"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-07-02","conditions":"Pancreatic Cancer","enrollment":87},{"nctId":"NCT02280694","phase":"PHASE2","title":"Low Dose Metronomic Poly-chemotherapy for Metastatic CRC","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2015-01","conditions":"Colorectal Cancer","enrollment":45},{"nctId":"NCT01869192","phase":"PHASE2","title":"Phase II Trial for Large ER-Negative Breast Cancers","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2003-03-05","conditions":"Malignant Neoplasm of Female Breast","enrollment":72},{"nctId":"NCT01131195","phase":"PHASE3","title":"Metronomic Therapy in Metastatic Breast Cancer.","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-07-19","conditions":"Breast Cancer","enrollment":139},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT00301925","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2005-12-16","conditions":"Breast Cancer","enrollment":4400},{"nctId":"NCT02004262","phase":"PHASE2","title":"Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting","status":"COMPLETED","sponsor":"Aduro Biotech, Inc.","startDate":"2014-02-05","conditions":"2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer","enrollment":303},{"nctId":"NCT03507465","phase":"PHASE2, PHASE3","title":"Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2017-11-29","conditions":"Breast Cancer","enrollment":290},{"nctId":"NCT00194779","phase":"PHASE2","title":"Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-10","conditions":"Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer","enrollment":50},{"nctId":"NCT02664103","phase":"PHASE2","title":"Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-23","conditions":"Breast Cancer Metastatic","enrollment":2},{"nctId":"NCT02271464","phase":"PHASE2","title":"Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2012-03","conditions":"Metastatic Colorectal Cancer","enrollment":232},{"nctId":"NCT00408408","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2006-11","conditions":"Breast Cancer","enrollment":1206},{"nctId":"NCT03085368","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-03-01","conditions":"HER2-positive Breast Cancer","enrollment":482},{"nctId":"NCT01227408","phase":"PHASE2","title":"Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2009-02","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01642771","phase":"PHASE3","title":"Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"China Breast Cancer Clinical Study Group","startDate":"2012-06","conditions":"Breast Cancer","enrollment":636},{"nctId":"NCT01507103","phase":"PHASE2","title":"Tecemotide (L-BLP25) in Rectal Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-02","conditions":"Rectal Cancer","enrollment":124},{"nctId":"NCT00024102","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-09","conditions":"Breast Cancer","enrollment":633},{"nctId":"NCT02846428","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT02842099","phase":"PHASE2","title":"Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2014-01","conditions":"Breast Cancer","enrollment":500},{"nctId":"NCT01204437","phase":"PHASE2, PHASE3","title":"Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2009-03","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT00235235","phase":"","title":"A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer","status":"TERMINATED","sponsor":"Hoosier Cancer Research Network","startDate":"2005-09","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT01067989","phase":"PHASE2","title":"Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer","status":"TERMINATED","sponsor":"HaEmek Medical Center, Israel","startDate":"2010-03","conditions":"Chemotherapy, Breast Cancer, Metastatic","enrollment":22},{"nctId":"NCT00146588","phase":"NA","title":"Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer","status":"COMPLETED","sponsor":"Craig A. Bunnell, MD, MPH","startDate":"2002-04","conditions":"Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer","enrollment":55},{"nctId":"NCT01969032","phase":"PHASE2","title":"Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Russian Academy of Medical Sciences","startDate":"2011-08","conditions":"Triple Negative Breast Cancer","enrollment":41},{"nctId":"NCT00196872","phase":"PHASE3","title":"A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2004-07","conditions":"Breast Cancer","enrollment":3000},{"nctId":"NCT02115152","phase":"PHASE2","title":"Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2014-06","conditions":"Stage II Breast Cancer, Stage III Breast Cancer","enrollment":100},{"nctId":"NCT00121134","phase":"NA","title":"Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer","status":"COMPLETED","sponsor":"Harold J. Burstein, MD, PhD","startDate":"2005-06","conditions":"Breast Cancer","enrollment":164},{"nctId":"NCT00262067","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","status":"UNKNOWN","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Metastatic Breast Cancer","enrollment":1237},{"nctId":"NCT00288002","phase":"PHASE3","title":"Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2005-01","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT00795678","phase":"","title":"Chemotherapeutic Agents in Brain/Breast","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":10},{"nctId":"NCT00107276","phase":"PHASE2","title":"S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2005-08","conditions":"Breast Cancer","enrollment":112},{"nctId":"NCT00005908","phase":"PHASE2","title":"Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-06","conditions":"Breast Cancer, Breast Neoplasm","enrollment":30},{"nctId":"NCT00008034","phase":"PHASE1","title":"Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2000-02","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT01641406","phase":"PHASE2","title":"\"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer\"","status":"UNKNOWN","sponsor":"Auxilio Mutuo Cancer Center","startDate":"2011-03","conditions":"Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma","enrollment":60},{"nctId":"NCT00830544","phase":"PHASE2","title":"Study of Neoadjuvant Chemotherapy of Breast Cancer","status":"UNKNOWN","sponsor":"Auxilio Mutuo Cancer Center","startDate":"2008-07","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT01526512","phase":"PHASE2","title":"Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2011-12","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT00050167","phase":"PHASE1","title":"Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-11","conditions":"Breast Cancer","enrollment":603},{"nctId":"NCT01415336","phase":"PHASE2, PHASE3","title":"AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2010-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT00352378","phase":"PHASE3","title":"Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2002-06","conditions":"Breast Cancer","enrollment":209},{"nctId":"NCT00589901","phase":"PHASE2","title":"An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2006-08","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT00114816","phase":"PHASE3","title":"Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer","status":"COMPLETED","sponsor":"Finnish Breast Cancer Group","startDate":"2004-01","conditions":"Breast Cancer","enrollment":1500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Capecitabine, Cyclophosphamide","genericName":"Capecitabine, Cyclophosphamide","companyName":"Vastra Gotaland Region","companyId":"vastra-gotaland-region","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Cyclophosphamide is an alkylating agent that attaches an alkyl group to the DNA of cancer cells, thereby interfering with their replication. Used for Metastatic breast cancer, Advanced colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}